Compare Flagstar Bank NA (FLG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Merck & Co., Inc. — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.71B), while Merck & Co., Inc. trades at $141.96 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 74.6× Flagstar Bank NA's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Merck & Co., Inc. for 98 Days on average.
| FLG | MRK | |
|---|---|---|
Market Cap | $4.71B | $351.28B |
Volume | 7,410,589 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $15.36 | $156.43 |
52-Week Low | $10.72 | $82.49 |
Typical Hold Time | 21 Days | 98 Days |
Enterprise Value | $15.25B | $398.04B |
Dividend Yield | 0.35% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $11.30, down 2.25% on the day, with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with Q2 2026 marking the third consecutive profitable quarter, though it missed EPS estimates. Analyst sentiment remains positive with a $17.07 consensus price target representing 51% upside potential. Recent strategic developments include a $250 million share repurchase program and a new core banking partnership with Fiserv.
The stock presents a compelling value opportunity trading at 0.62x book value, but faces risks from volatile earnings performance and negative cash flow trends. While analyst consensus is bullish with 60% buy ratings, investors should monitor execution on profitability improvements and the impact of recent strategic initiatives on long-term growth.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
